| Revision as of 19:00, 19 June 2011 editNitraus (talk | contribs)Extended confirmed users2,699 editsmNo edit summary← Previous edit |
Latest revision as of 06:55, 27 September 2023 edit undoPashihiko (talk | contribs)Extended confirmed users3,559 editsNo edit summary |
| (30 intermediate revisions by 24 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Noref|date=June 2009}} |
|
|
|
{{Refimprove|date=July 2016}} |
| ⚫ |
{{drugbox | verifiedrevid = 400296986 |
|
|
|
{{Drugbox |
|
| |
|
|
|
| Verifiedfields = changed |
| ⚫ |
| IUPAC_name = (3''S'',4''R'')-3-ethyl-1-methyl-4-phenylpiperidin-4-yl propionate |
|
|
⚫ |
| verifiedrevid = 447991486 |
| ⚫ |
| image = Alphameprodine.svg |
|
|
⚫ |
| IUPAC_name = (3''S'',4''R'')-3-ethyl-1-methyl-4-phenylpiperidin-4-yl propionate |
| ⚫ |
| imagename = Alpha-meprodine |
|
|
⚫ |
| image = Alphameprodine.svg |
|
| width = 160 |
|
| width = 160 |
|
| InChI = 1/C17H25NO2/c1-4-14-13-18(3)12-11-17(14,20-16(19)5-2)15-9-7-6-8-10-15/h6-10,14H,4-5,11-13H2,1-3H3/t14-,17-/m0/s1 |
|
|
⚫ |
| caption = Alpha-meprodine |
|
| InChIKey = ODEGQXRCQDVXSJ-YOEHRIQHBS |
|
|
|
<!--Clinical data--> |
|
|
| tradename = |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
|
|
| legal_AU = S9 |
|
|
| legal_BR = A1 |
|
|
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=] |language=pt-BR |publication-date=2023-04-04}}</ref> |
|
⚫ |
| legal_CA = Schedule I |
|
⚫ |
| legal_UK = <!-- Class A --> |
|
⚫ |
| legal_US = Schedule I |
|
|
| legal_DE = Anlage I |
|
⚫ |
| routes_of_administration = |
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
⚫ |
| CAS_number = 468-51-9 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 1177I648L1 |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
|
| KEGG = D12666 |
|
⚫ |
| ATC_prefix = none |
|
⚫ |
| ATC_suffix = |
|
⚫ |
| PubChem = 61119 |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEMBL = 2104027 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
⚫ |
| ChemSpiderID = 16736823 |
|
|
<!--Chemical data--> |
|
⚫ |
| C=17 | H=25 | N=1 | O=2 |
|
| smiles = CC1CN(C)CC1(OC(=O)CC)c2ccccc2 |
|
| smiles = CC1CN(C)CC1(OC(=O)CC)c2ccccc2 |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| Line 13: |
Line 50: |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = ODEGQXRCQDVXSJ-YOEHRIQHSA-N |
|
| StdInChIKey = ODEGQXRCQDVXSJ-YOEHRIQHSA-N |
| ⚫ |
| CAS_number = 468-51-9 |
|
| ⚫ |
| ATC_prefix = none |
|
| ⚫ |
| ATC_suffix = |
|
| ⚫ |
| PubChem = 61119 |
|
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ⚫ |
| ChemSpiderID=16736823 |
|
| ⚫ |
| DrugBank = |
|
| ⚫ |
| C = 17 | H = 25 | N = 1 | O = 2 |
|
|
| molecular_weight = 275.39 g/mol |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= |
|
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = <!-- Schedule I --> |
|
| ⚫ |
| legal_UK = <!-- Class A --> |
|
| ⚫ |
| legal_US = <!-- Schedule I --> |
|
|
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
|
|
|
|
'''Meprodine''' is an ] ] that is an ] of ] (meperidine). It is closely related to the drug ], the only difference being that meprodine has an ] rather than a ] at the 3-position of the ] ring. |
|
'''Meprodine''' is an ] ] that is an ] of ] (meperidine). It is closely related to the drug ], the only difference being that meprodine has an ] rather than a ] at the 3-position of the ] ring.<ref>{{cite book | vauthors = Morton IK, Hall JM |title=Concise Dictionary of Pharmacological Agents : Properties and Synonyms. |date=October 2012 |publisher=Springer |location=New York |isbn=978-94-010-5907-7 | page = 176 | chapter = Meprodine | chapter-url = https://books.google.com/books?id=tsjrCAAAQBAJ&dq=Meprodine&pg=PA176 }}</ref> |
|
|
|
|
|
As with prodine, there are two ]s of meprodine, alpha-meprodine and beta-meprodine, with the alpha isomer having been more widely used. |
|
As with prodine, there are two ]s of meprodine, alpha-meprodine and beta-meprodine, with the alpha isomer having been more widely used. Alphameprodine (ACSCN 9604) and betameprodine (ACSCN 9608) are both Schedule I Narcotic controlled substances in the United States, both with annual aggregate manufacturing quotas of 2 grammes as of 2014.<ref>{{cite web | title = Quotas - 2014 | url = http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm | work = Diversion Control Division | publisher = Drug Enforcement Administration, U.S. Department of Justice }}</ref> |
|
|
|
|
|
Meprodine has similar effects to other opioids, and produces analgesia, sedation and euphoria. Side effects can include ], ] and potentially serious ] which can be life-threatening. |
|
Meprodine has similar effects to other opioids, and produces analgesia, sedation and euphoria. Side effects can include ], ] and potentially serious ] which can be life-threatening. |
|
|
|
|
|
==Legal Status== |
|
|
|
|
|
===Australia=== |
|
|
Meprodine is considered a Schedule 9 prohibited substance in Australia under the ] (February 2017).<ref name="Poisons Standard">{{cite web | title = Poisons Standard | date = October 2015 | url = https://www.legislation.gov.au/Details/F2017L00057 | publisher = Australian Government | work = Federal Register of Legislation }}</ref> A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.<ref name="Poisons Standard" /> |
|
|
|
|
|
== References == |
|
== References == |
|
|
{{Reflist}} |
|
<references /> |
|
|
|
|
|
|
|
{{Opioidergics}} |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
| ⚫ |
{{analgesic-stub}} |
|
|
|
|
|
|
⚫ |
{{analgesic-stub}} |
|
] |
|
|
] |
|
|
] |
|